Vaccine policy changes and epidemiology of poliomyelitis in the United States

JAMA

Volumn 292, Issue 14, 2004, Pages 1696-1701

  Alexander, Lorraine Niño ^a,e   Seward, Jane F ^a   Santibanez, Tammy A ^a   Pallansch, Mark A ^b   Kew, Olen M ^b   Prevots, D Rebecca ^a,c   Strebel, Peter M ^a   Cono, Joanne ^a   Wharton, Melinda ^a   Orenstein, Walter A ^a,d   Sutter, Roland W ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d EMORY UNIVERSITY   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; LABORATORY TEST; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UNITED STATES; VACCINATION; VACCINE ASSOCIATED PARALYTIC POLIOMYELITIS; ARTICLE; IMMUNIZATION; POLICY; PREVENTIVE HEALTH SERVICE; RISK; STANDARD; STATISTICS;

HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; ORGANIZATIONAL POLICY; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; POPULATION SURVEILLANCE; RISK; UNITED STATES; VACCINATION;

EID: 5044251393     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.14.1696     Document Type: Review

References (42)

1. Centers for Disease Control. CDC Annual Summary: Reported Morbidity and Mortality in the United States. Atlanta, Ga: Centers for Disease Control; 1981.
2. Schonberger LB, Sullivan-Bolyai JZ, Bryan JA. Poliomyelitis in the United States. Adv Neurol. 1978;19:217-227.
3. Centers for Disease Control, Poliomyelitis - United States, 1975-1984. MMWR Morb Mortal Wkly Rep. 1986;35:180-182.
4. Rico-Hesse R, Pallansch MA, Nottay BK, Kew OM. Geographic distribution of wild poliovirus type 1 genotypes. Virology. 1987;160:311-322.
5. Sutter R, Cochi S, Melnick J. Live attenuated poliovirus vaccines. In: Orenstein WA, ed. Vaccines. Philadelphia, Pa: WB Saunders Co; 1999:364-408.
6. Luther T. The Association of Cases of Poliomyelitis with the Use of Type III Oral Polio Vaccines. Washington, DC: US Dept of Health, Education, and Welfare; 1962:1-8.
7. Henderson DA, Witte JJ, Morris L, Langmuir AD. Paralytic disease associated with oral polio vaccines. JAMA. 1964;190:41-48.
8. Schonberger LB, McGowan JE Jr, Gregg MB. Vaccine-associated poliomyelitis in the United States, 1961-1972. Am J Epedemiol. 1976;104:202-211.
9. Nkowane BM, Wassilak SG, Orenstein WA, et al. Vaccine-associated paralytic poliomyelitis. JAMA. 1987;257:1335-1340.
10. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992;14:568-579.
11. Esteves K. Safety of oral poliomyelitis vaccine. Bull World Health Organ. 1988;66:739-746.
12. Centers for Disease Control and Prevention. Global Polio Eradication Initiative strategic plan, 2004. MMWR Morb Mortal Wkly Rep. 2004;53:107-108.
13. Institute of Medicine. Evaluation of Poliomyelitis Vaccines. Washington, DC: National Academy Press; 1977:75.
14. Institute of Medicine. An Evaluation of Poliomyelitis Vaccine Policy Options. Washington, DC: National Academy of Sciences; 1988.
15. Institute of Medicine. Vaccine Safety Forum: Options for Poliomyelitis Vaccination in the United States: Workshop Summary. Washington, DC: National Academy Press; 1996.
16. Marwick C. Polio vaccine schedule will change, but when? JAMA. 1996;275:827.
17. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. [erratum appears in MMWR Morb Mortal WkLy Rep. 1997;46:183]. MMWR Recomm Rep. 1997;46(RR-3):1-25.
18. American Academy of Pediatrics Committee on Infectious Diseases. Poliomyelitis prevention: recommendations for use of inactivated poliovirusvacine and live oral poliovirus vaccine. Pediatrics. 1997;99:300-305.
19. Kohberger RC, Sutter RW, Rhodes PH. Modeling the five immunization schedule options. Presented at; Institute of Medicine Polio Workshop; June 7, 1995; Washington, DC.
20. Zimmerman RK, Spann SJ. Poliovirus vaccine options. Am Fam Physician. 1999;59:113-118.
21. American Academy of Pediatrics Committee on Infectious Diseases. Poliomyelitis prevention: revised recommendations for use of inactivated and live oral poliovirus vaccines. Pediatrics. 1999;103:171-172.
22. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of poliomyelitis: recommendations for use of only inactivated poliovirus vaccine for routine immunization. Pediatrics. 1999;104:1404-1406.
23. Poliomyelitis prevention in the United States - updated recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2000;49:1-22.
24. Prevots DR, Sutter RW, Strebel PM, Weibel RE, Cochi SL. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Arch Pediatr Adolesc Med. 1994;148:479-485.
25. Weibel RE, Benor DE. Reporting vaccine-associated paralytic poliomyelitis. Am J Public Health. 1996;86:734-737.
26. Centers for Disease Control and Prevention. National Immunization Survey (NIS). Available at: http://www.cdc.gov/nip/coverage/default.htm#NIS. Accessed July 2004.
27. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep. 1997;46(RR-10):1-55.
28. Sutter RW, Brink EW, Cochi SL, et al. A new epidemiologic and laboratory classification system for paralytic poliomyelitis cases. Am J Public Health. 1989;79:495-498.
29. Schmidt N. Cell culture procedures for diagnostic virology. In: Emmons R, ed. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. Washington, DC: American Public Health Association; 1989:51-100.
30. Nottay BK, Kew OM, Hatch MH, Heyward JT, Obijeski JF. Molecular variation of type 1 vaccine-related and wild polioviruses during replication in humans. Virology. 1981;108:405-423.
31. De L, Nottay B, Yang CF, Holloway BP, Pallansch M, Kew O. Identification of vaccine-related polioviruses by hybridization with specific RNA probes. J Clin Microbiol. 1995;33:562-571.
32. Yang CF, De L, Holloway BP, Pallansch MA, Kew OM. Detection and identification of vaccine-related polioviruses by the polymerase chain reaction. Virus Res. 1991;20:159-179.
33. Paralytic poliomyelitis-United States, 1980-1994. MMWR Morb Mortal Wkly Rep. 1997;46:79-83.
34. Ventura SJ, Martin J, Curtin M, Menacker F, Hamilton BE. Births: final data for 1999. Natl Vital Stat Rep. 2001;49:1-100.
35. Lindegren ML, Kobrynski L, Rasmussen SA, et al. Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm Rep. 2004;53:1-29.
36. Sutter R, Prevots D. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med. 1994;11:426, 429-430, 435-438.
37. Wattigney WA, Mootrey GT, Braun MM, Chen RT. Surveillance for poliovirus vaccine adverse events, 1991 to 1998, Pediatrics. 2001;107:E83.
38. Kolasa MS, Bisgard KM, Prevots DR, Desai SN, Dibling K. Parental attitudes toward multiple poliovirus injections following a provider recommendation. Public Health Rep. 2001;116:282-288.
39. Impact of the sequential IPV/OPV schedule on vaccination coverage levels - United States, 1997. MMWR Morb Mortal Wkly Rep. 1998;47:1017-1019.
40. Taylor JA, Darden PM, Brooks DA, et al. Impact of the change to inactivated poliovirus vaccine on the immunization status of young children in the United States. Pediatrics. 2001;107:E90.
41. Varughese PV, Carter AO, Acres SE, Furesz J. Eradication of indigenous poliomyelitis in Canada. Can J Public Health. 1989;80:363-368.
42. Joce R, Wood D, Brown D, Begg N. Paralytic poliomyelitis in England and Wales, 1985-91. BMJ. 1992:305:79-82.